Introduction
The limb-girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous disorders characterized by predominant proximal muscle weakness with histopathological signs of progressive degeneration in muscle. 1 The estimated incidence for all forms of LGMDs is 1:100,000, the clinical spectrum of LGMDs can vary from severe childhood forms with early loss of independent ambulation to milder adult-onset slowly progressive subtypes. 2 They are divided into two major groups according to the hereditary trait: autosomal dominant (AD) forms that are indicated as LGMD type D, autosomal recessive (AR) forms that are classified as LGMD type R. 1 One subtype of dominant LGMD is due to a mutation of TNPO3 gene (LGMD D2). This rare disorder was first identified in a large Italo-Spanish family 3 in which patients presented proximal limbgirdle muscles weakness with variable onset ranging from 1 to 58 years. 4 In this family, the disease locus has been mapped to chromosome 7q32.1-32.2. 4 In 2013, using the next-generation sequencing (NGS) technique we identified a heterozygous frame-shift variant in the Transportin-3 (TNPO3) gene, that encodes Transportin-3. 5, 6 Transportin-3 is a nuclear protein member of the importin beta superfamily that imports serine-arginine-rich proteins into the nucleus, which is important for mRNA splicing. The clinical phenotype of LGMD D2 is characterized by severe weakness occurring first in the pelvic girdle muscle, then the shoulder girdle. In severe clinical cases, distal muscle weakness, winging scapulae, scoliosis and occasional facial weakness are present. No cognitive impairment or cardiac involvement has been observed (Table 1) . Only in the juvenile-onset severe phenotype, respiratory involvement has been reported. 7 We present a family with a congenital myopathy-LGMD phenotype in a child and his mother of Hungarian origin. A written informed consent was obtained from the mother (Patient 1) to publish the medical data and images of both her and her son (Patient 2). Molecular analysis, magnetic resonance imaging (MRI), histopathological study, and a assessment of quality of life were performed in this new A new family with transportinopathy: increased clinical heterogeneity family of LGMD D2 and compared with previous findings in the first reported family. 8, 9 Case report Patient 1 Patient 1, a 43-year-old woman of Hungarian origin, had two sons, the first, Patient 2, affected by LGMD D2, whereas the second, 10 years old, is healthy. Her parents were reported to be unaffected, but refused further DNA investigation.
The woman presented the first symptoms during her childhood: she started walking at 15 months and was always weak compared with peers. Electromyography (EMG) was performed at age 6 and myopathic alterations were found. During her second pregnancy at 30 years, she underwent a C-section, presented difficulty breathing and felt 'paralyzed'. At age 41, she had elevated creatine kinase (CK) then she presented decreased muscle strength in the forearm and finger extensors and in the back muscles. She had also a proximal weakness primarily affecting proximal lower limb muscles.
On the last exam at age 43, she was able to walk, but had difficulty running. She complained of frequent falls, had difficulty keeping legs elevated or raising from the floor (Gower's manoeuvre) and had to climb stairs using the handrail. She has reduced forced vital capacity (FVC) on spirometry (57%) and presented difficulty in her speech and swallowing. She had no cardiac involvement or cognitive impairment.
On last neuromuscular evaluation (IRCCS San Camillo Hospital, March 2018), specific clinical myopathic signs were observed such as pigeon toe-feet and kyphoscoliosis.
Muscle strength graded by Medical Research Council (MRC) scale 10 showed severe muscle LGMD D2
Disease symbol
LGMD D2 or 1F 
Histopathological studies
In the child muscle biopsy, morphologic findings by haematoxylin-eosin (HE) staining showed prominent fibre atrophy with acid ATPase stain (pH 4) with a 92% type 1 fibre predominance (Figure 2A and B) was observed. NADH-TR showed the abnormal presence of mitochondrial rims and periodic acid-Schiff (PAS) reaction detected focal glycogen accumulation in some fibres ( Figure 2C and D) . Ultrastructural analysis showed abnormal mitochondrial accumulation, myelinoid bodies and occasional cytoplasmic bodies; several abnormal nuclei had a fenestrated appearance ( Figure 2E -G).
Muscle MRI
Muscle MRI was performed in both patients using a 1.5-T MRI scanner in T1-weighted sequences; muscle pattern was ranked according to Mercuri scale. 13 Muscle MRI of patient 1 revealed marked atrophy, fatty tissue replacement in the pelvic girdle and anterior thigh muscles, especially in vastus lateralis, vastus medialis and intermedius, whereas in posterior thigh semitendinous and semimembranous muscles were relatively spared ( Figure  3A ). Posterior leg muscles were characterized by marked atrophy, in particular, soleus and gastrocnemius muscles were completely replaced by fatty infiltration ( Figure 3B ).
In patient 2, muscle MRI showed a pronounced hypotrophy of anterior thigh muscles, whereas leg muscles were preserved ( Figure 3C and D) .
Mutation analysis
Genomic DNA was extracted from cultured fibroblasts of patient 1, analysed by whole exome sequencing (WES) and confirmed by Sanger sequencing. A heterozygous frameshift single base pair deletion c.2767delC (p.Arg923Aspfs*17) in exon 23 of TNPO3 gene was identified in both the mother and son genomic DNA. The number associated to the reference sequence is NM_012470.3: c.2767del; NP_036602.1: p.(Arg923Aspfs*17). This variant has not previously been reported and in silico predicted to be damaging (PoliPhen score 0.992; sensitivity 0.49; specificity 0.95).
The mutation identified is very similar and close to the first described mutation 5 because it always involves the C-terminal therefore the final effect might be the same. The deletion of the base is in the codon immediately preceding to the other family variant (base position chr7: 128,597,310; NM_012470.3: c.2771delA, NP_036602.1p. (Ter924Cys)) and could be resulting in a longer protein (15 aa longer) than the wild type. 
Discussion
Clinical, molecular, histopathological and radiological data, along with electron microscopy findings have been described so far only in a TNPO3 family. 9, 6 This dominant LGMD is characterized by clinical heterogeneity. The disorder has onset in childhood or adolescence, but also frequently in adulthood; in adults, it has a benign course compatible with a normal life. In the Italo-Spanish family, the main characteristic features and possible clues for diagnosis observed were abnormally long finger (arachnodactyly), pes cavus, Achilles retraction, and kyphoscoliosis (Table 1) . On the other hand, the main clinical signs observed in Hungarian patients were the difficulty in lifting arms over the head, due to scapular winging, and inability to lift legs from the bed.
Respiratory insufficiency might occur around 20-30 years in early onset cases: 3 the mother had severe impairment of the respiratory function, while the son presented normal spirometry.
Gamez et al. 3 in the biopsy of the Italo-Spanish
LGMD patients observed diffuse atrophic fibres, basophilic cytoplasmic regions with spots of cytoplasmic lysosomal acid phosphatase reaction. By an ultrastructural study, Cenacchi et al. 8 showed fibre atrophy, abnormal mitochondria accumulations with rare paracrystalline-like inclusions and autophagosomal vacuoles containing cytoplasmic debris and myeloid bodies. Similar histopathological and ultrastructural changes were observed in the biopsy of the son such as fibre atrophy, mitochondrial accumulation, myelinoid bodies, autophagosomal vacuoles and central fenestrated nuclei.
In the Italo-Spanish family, the mutation was identified as a single nucleotide deletion (c.2771delA, p.X924C, exon 22) in the TNPO3 gene not present in databases, which determines a nonstop mutation and consequently a 15-aminoacid extension of the C-terminus of the protein. 5, 6 Molecular analysis showed that the causative mutation of LGMD D2 in the Hungarian patients is due to a single nucleotide deletion in the termination codon of transportin 3 in exon 23 and might result in TNPO3 reduction. In this infantile-onset case, there was a congenital myopathy phenotype. The neurological examination highlighted this peculiar aspect: the child presented a severe phenotype with hypotonia and had thin and weak muscles.
Data derived from MRI study in our cases of this new family confirm a pattern of early onset and a late onset with proximal muscle involvement. The MRI changes in the mother at age 43 were more marked than in her son and were compatible with an LGMD phenotype. 9 This AD disorder has been previously demonstrated to have incomplete penetrance in the original family. 14 The lack of clinical signs in the parent(s) of patient 1 could be due to an incomplete penetrance rather than being a spontaneous mutation.
Transportin 3 orchestrates nuclear import of splicing factors and it is implicated in HIV resistance. 15 The role of TNPO3 protein in muscle is unknown, but its involvement in nuclear import of splicing factors and protein involved in the RNA metabolism leads to a hypothesis about how TNPO3 mutation can cause LGMD D2.
The mutations abolish the stop codon, therefore the synthesis of a limited amount of TNPO3 protein with increased molecular weight is expected to occur in association with the mutation found in this family: a perturbed nuclear-myofibrillar interaction could result in myofibrillar disarray.
Regarding INQoL in our LGMD case, the results are consistent with those published by Peric et al. 16 in 46 patients with LGMD. In both cases, the scores were similar, showing worse selfreported evaluation for weakness and fatigue and better results for social relationships and emotions. There was no effect on independent life.
The clinical features in these two patients of Hungarian family add new data to the spectrum of the clinical phenotypes so far described in LGMD D2. In particular, the clinical features appear severe in this family because the onset of symptoms was in the first year of life, including distal, axial, facial and bulbar weakness. However, onset in the first years of childhood, 3, 4, 6, 9 delayed motor skills, 6 distal leg weakness, 3, 6, 9 axial weakness, 9 facial weakness 3,9 and bulbar signs 9 are also a feature of previously reported cases, and epigenetic and genetic modifiers are probably important in determining the onset, the characteristics and the progression of this disorder.
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